Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 100.4% in August

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,503,479 shares, an increase of 100.4% from the August 15th total of 1,249,260 shares. Currently, 18.4% of the company’s stock are short sold. Based on an average daily volume of 49,532,777 shares, the days-to-cover ratio is presently 0.1 days.

Analysts Set New Price Targets

VVOS has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Friday, July 17th. Ascendiant Capital Markets boosted their target price on shares of Vivos Therapeutics from $3.00 to $3.10 and gave the company a “buy” rating in a report on Thursday, June 4th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $2.80.

Institutional Investors Weigh In On Vivos Therapeutics

An institutional investor recently bought a new position in Vivos Therapeutics stock. Sequoia Financial Advisors LLC acquired a new stake in shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 24,000 shares of the company’s stock, valued at approximately $28,000. Sequoia Financial Advisors LLC owned 0.18% of Vivos Therapeutics at the end of the most recent reporting period. 26.35% of the stock is currently owned by hedge funds and other institutional investors.

Vivos Therapeutics Stock Down 8.9%

Shares of Vivos Therapeutics stock traded down $0.02 on Tuesday, hitting $0.16. The stock had a trading volume of 1,243,276 shares, compared to its average volume of 4,685,058. The stock’s 50-day simple moving average is $0.32 and its two-hundred day simple moving average is $0.70. Vivos Therapeutics has a one year low of $0.16 and a one year high of $3.70. The stock has a market cap of $2.24 million, a price-to-earnings ratio of -0.08 and a beta of 6.04.

Vivos Therapeutics (NASDAQ:VVOS) last announced its earnings results on Friday, August 14th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.10. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 122.00%.The company had revenue of $5.15 million during the quarter, compared to the consensus estimate of $5.63 million. As a group, equities analysts predict that Vivos Therapeutics will post -1.54 EPS for the current fiscal year.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.